Jade Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
JBIO$15.60+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Description | Form | Date | Number | Included Herewith |
|---|---|---|---|---|---|
| 2.1† | Agreement and Plan of Merger, dated as of October 30, 2024, by and among Aerovate Therapeutics, Inc., Caribbean Merger Sub I, Inc., Caribbean Merger Sub II, LLC and Jade Biosciences, Inc. | 8-K | 10-31-2024 | 2.1 | |
| 2.2 | Plan of Conversion. | 8-K | 5-1-2025 | 2.2 | |
| 3.1 | Amended and Restated Articles of Incorporation of the Company | 8-K | 6-11-2026 | 3.1 | |
| 3.2 | Amended and Restated Bylaws of the Company, effective as of June 9, 2026. | 8-K | 6-11-2026 | 3.2 | |
| 3.3 | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock, effective April 28, 2025. | 8-K | 5-1-2025 | 3.7 | |
| 4.1 | Form of Pre-Funded Warrant, dated April 28, 2025. | 8-K | 5-1-2025 | 4.1 | |
| 4.2 | Form of Pre-Funded Warrant (October 2025 PIPE). | 8-K | 10-7-2025 | 4.1 | |
| 4.3 | Parade Warrant, dated December 31, 2025. | 10-K | 3-6-2026 | 4.3 | |
| 10.1 | Open Market Sale AgreementSM dated May 7, 2026, by and between Jefferies LLC and Jade Biosciences, Inc. | S-3 | 5-7-2026 | 1.2 | |
| 10.2††† | JADE301 License Agreement, dated June 29, 2026, by and between Paragon Therapeutics, Inc. and Jade Biosciences, Inc. | X | |||
| 10.3# | Form of Grant Notice for Stock Options and Standard Terms and Conditions for Stock Options under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (Directors) (adopted June 18, 2026). | X | |||
| 10.4# | Form of Grant Notice for Stock Options and Standard Terms and Conditions for Stock Options under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (Employees) (adopted June 18, 2026). | X | |||
| 10.5# | Form of Grant Notice for Stock Options and Standard Terms and Conditions for Stock Options under the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan (adopted June 18, 2026). | X | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Furnished herewith. The certifications on Exhibits 32.1 and 32.2 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.